Frameshift mutation spectra overlap between constitutional mismatch repair deficiency tumors and Lynch syndrome tumors.

Autor: Song Y; Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, United States of America., Baugher RN; Molecular Diagnostics Laboratory, Frederick National Laboratory for Cancer Research, Frederick, United States of America., Young TB; Molecular Diagnostics Laboratory, Frederick National Laboratory for Cancer Research, Frederick, United States of America., Somerville B; Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, United States of America., Mori Y; Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, United States of America., Pinto LA; Vaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, United States of America., Nichols KE; Division of Cancer Predisposition, St. Jude Children's Research Hospital, Memphis, United States of America., Shoemaker RH; Division of Cancer Prevention, National Cancer Institute, Bethesda, United States of America.

Publikováno v: The Journal of clinical investigation [J Clin Invest] 2024 Oct 22. Date of Electronic Publication: 2024 Oct 22.

Organoids and metastatic orthotopic mouse model for mismatch repair-deficient colorectal cancer.

Autor: Song Y; Frederick National Laboratory for Cancer Research, Vaccine, Immunity, and Cancer Directorate, Frederick, MD, United States., Kerr TD; Frederick National Laboratory for Cancer Research, Vaccine, Immunity, and Cancer Directorate, Frederick, MD, United States., Sanders C; Frederick National Laboratory for Cancer Research, Laboratory Animal Sciences Program, Frederick, MD, United States., Dai L; Frederick National Laboratory for Cancer Research, Vaccine, Immunity, and Cancer Directorate, Frederick, MD, United States., Baxter SS; Frederick National Laboratory for Cancer Research, Vaccine, Immunity, and Cancer Directorate, Frederick, MD, United States., Somerville B; Frederick National Laboratory for Cancer Research, Vaccine, Immunity, and Cancer Directorate, Frederick, MD, United States., Baugher RN; Frederick National Laboratory for Cancer Research, Clinical Laboratory Improvement Amendments (CLIA) Molecular Diagnostics Laboratory, Frederick, MD, United States., Mellott SD; Frederick National Laboratory for Cancer Research, Clinical Laboratory Improvement Amendments (CLIA) Molecular Diagnostics Laboratory, Frederick, MD, United States., Young TB; Frederick National Laboratory for Cancer Research, Clinical Laboratory Improvement Amendments (CLIA) Molecular Diagnostics Laboratory, Frederick, MD, United States., Lawhorn HE; Frederick National Laboratory for Cancer Research, Clinical Laboratory Improvement Amendments (CLIA) Molecular Diagnostics Laboratory, Frederick, MD, United States., Plona TM; Frederick National Laboratory for Cancer Research, Clinical Laboratory Improvement Amendments (CLIA) Molecular Diagnostics Laboratory, Frederick, MD, United States., Xu B; Frederick National Laboratory for Cancer Research, Genomics Laboratory, Frederick, MD, United States., Wei L; Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States., Hu Q; Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States., Liu S; Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States., Hutson A; Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States., Karim B; Molecular Histopathology Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, United States., Burkett S; Molecular Cytogenetics Core Facility, National Cancer Institute, Frederick, MD, United States., Difilippantonio S; Frederick National Laboratory for Cancer Research, Laboratory Animal Sciences Program, Frederick, MD, United States., Pinto L; Frederick National Laboratory for Cancer Research, Vaccine, Immunity, and Cancer Directorate, Frederick, MD, United States., Gebert J; Department of Applied Tumor Biology, Institute of Pathology, University of Heidelberg, Heidelberg, Germany., Kloor M; Department of Applied Tumor Biology, Institute of Pathology, University of Heidelberg, Heidelberg, Germany., Lipkin SM; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY, United States., Sei S; Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, United States., Shoemaker RH; Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, United States.

Publikováno v: Frontiers in oncology [Front Oncol] 2023 Sep 08; Vol. 13, pp. 1223915. Date of Electronic Publication: 2023 Sep 08 (Print Publication: 2023).

A novel mouse model of PMS2 founder mutation that causes mismatch repair defect due to aberrant splicing.

Autor: Biswas K; Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA., Couillard M; The Lady Davis Institute of the Jewish General Hospital, McGill University, Montreal, QC, Canada., Cavallone L; The Lady Davis Institute of the Jewish General Hospital, McGill University, Montreal, QC, Canada., Burkett S; Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA., Stauffer S; Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA., Martin BK; Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.; Leidos Biomedical Research, Inc. Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Southon E; Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.; Leidos Biomedical Research, Inc. Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Reid S; Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA., Plona TM; CLIA Molecular Diagnostics Laboratory, Leidos Biomedical Research, Inc. Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Baugher RN; CLIA Molecular Diagnostics Laboratory, Leidos Biomedical Research, Inc. Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Mellott SD; CLIA Molecular Diagnostics Laboratory, Leidos Biomedical Research, Inc. Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Pike KM; CLIA Molecular Diagnostics Laboratory, Leidos Biomedical Research, Inc. Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Albaugh ME; Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.; Leidos Biomedical Research, Inc. Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Maedler-Kron C; Department of Pathology, McGill University, Montreal, QC, Canada., Hamel N; Department of Oncology, McGill University, Montreal, QC, Canada.; Department of Human Genetics, McGill University, Montreal, QC, Canada., Tessarollo L; Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA., Marcus V; Department of Pathology, McGill University, Montreal, QC, Canada., Foulkes WD; The Lady Davis Institute of the Jewish General Hospital, McGill University, Montreal, QC, Canada.; Department of Oncology, McGill University, Montreal, QC, Canada.; Department of Human Genetics, McGill University, Montreal, QC, Canada.; Department of Medical Genetics, Jewish General Hospital, McGill University, Montreal, QC, H3T 1E2, Canada.; Department of Medical Genetics and Cancer Research Program, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, H4A 3JI, Canada., Sharan SK; Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA. sharans@mail.nih.gov.

Publikováno v: Cell death & disease [Cell Death Dis] 2021 Sep 06; Vol. 12 (9), pp. 838. Date of Electronic Publication: 2021 Sep 06.

Pharmacogenomics Implementation at the National Institutes of Health Clinical Center.

Autor: Sissung TM; Clinical Pharmacology Program, Office of the Clinical Director, National Cancer Institute, Rockville, MD, USA., McKeeby JW; Department of Clinical Research Informatics, NIH Clinical Center, Bethesda, MD, USA., Patel J; Pharmacy Department, NIH Clinical Center, Bethesda, MD, USA., Lertora JJ; Clinical Pharmacology Program (2006-2016), NIH Clinical Center, Bethesda, MD, USA., Kumar P; Clinical Pharmacokinetics Research Laboratory, NIH Clinical Center, Bethesda, MD, USA., Flegel WA; Department of Transfusion Medicine, NIH Clinical Center, Bethesda, MD, USA., Adams SD; Department of Transfusion Medicine, NIH Clinical Center, Bethesda, MD, USA., Eckes EJ; Medical Surgical Specialties Service, Clinical Center Nursing Department, NIH, Bethesda, MD, USA., Mickey F; Department of Clinical Research Informatics, NIH Clinical Center, Bethesda, MD, USA., Plona TM; CLIA Molecular Diagnostics Laboratory, Cancer Research Technology Program, and Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA., Mellot SD; CLIA Molecular Diagnostics Laboratory, Cancer Research Technology Program, and Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA., Baugher RN; CLIA Molecular Diagnostics Laboratory, Cancer Research Technology Program, and Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA., Wu X; Genomics Laboratory, Cancer Research Technology Program, and Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA., Soppet DR; Genomics Laboratory, Cancer Research Technology Program, and Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA., Barcus ME; CLIA Molecular Diagnostics Laboratory, Cancer Research Technology Program, and Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA., Datta V; CLIA Molecular Diagnostics Laboratory, Cancer Research Technology Program, and Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA.; Molecular Characterization Laboratory, Cancer Research Technology Program, and Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA., Pike KM; CLIA Molecular Diagnostics Laboratory, Cancer Research Technology Program, and Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, USA., DiPatrizio G; Department of Clinical Research Informatics, NIH Clinical Center, Bethesda, MD, USA., Figg WD; Clinical Pharmacology Program, Office of the Clinical Director, National Cancer Institute, Rockville, MD, USA., Goldspiel BR; Pharmacy Department, NIH Clinical Center, Bethesda, MD, USA.

Publikováno v: Journal of clinical pharmacology [J Clin Pharmacol] 2017 Oct; Vol. 57 Suppl 10, pp. S67-S77.